Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study

Tan, Daniel S WDaniel S WTanKim, Sang-WeSang-WeKimPonce Aix, SantiagoSantiagoPonce AixSequist, Lecia VLecia VSequistSmit, Egbert FEgbert FSmitCHIH-HSIN YANGHida, ToyoakiToyoakiHidaToyozawa, RyoRyoToyozawaFelip, EnriquetaEnriquetaFelipWolf, JuergenJuergenWolfGrohé, ChristianChristianGrohéLeighl, Natasha BNatasha BLeighlRiely, GregoryGregoryRielyCui, XiaomingXiaomingCuiZou, MikeMikeZouGhebremariam, SamsonSamsonGhebremariamO'Sullivan-Djentuh, LeslieLeslieO'Sullivan-DjentuhBelli, RiccardoRiccardoBelliGiovannini, MonicaMonicaGiovanniniKim, Dong-WanDong-WanKim2023-03-022023-03-022022-090959-8049https://scholars.lib.ntu.edu.tw/handle/123456789/628836Nazartinib, a novel third-generation EGFR-tyrosine kinase inhibitor, previously demonstrated antitumor activity and manageable safety in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who received ≤ 3 prior lines of systemic therapy. Herein, we report phase 2 efficacy and safety of first-line nazartinib.enEGFR; NSCLC; Nazartinib; Third-generation EGFR-TKI; Treatment-naive[SDGs]SDG3Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyjournal article10.1016/j.ejca.2022.05.023358105532-s2.0-85133930125WOS:000829363200003https://api.elsevier.com/content/abstract/scopus_id/85133930125